These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976 [TBL] [Abstract][Full Text] [Related]
7. Discovery of a Novel BCL-X Pal P; Thummuri D; Lv D; Liu X; Zhang P; Hu W; Poddar SK; Hua N; Khan S; Yuan Y; Zhang X; Zhou D; Zheng G J Med Chem; 2021 Oct; 64(19):14230-14246. PubMed ID: 34533954 [TBL] [Abstract][Full Text] [Related]
8. A selective BCL-X Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461 [TBL] [Abstract][Full Text] [Related]
9. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones. Ishida T; Ciulli A SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537 [TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Evaluation of BCL-2 Targeting PROTACs. Bricelj A; Dora Ng YL; Gobec M; Kuchta R; Hu W; Javornik Š; Rožič M; Gütschow M; Zheng G; Krönke J; Steinebach C; Sosič I Chemistry; 2024 Aug; 30(45):e202400430. PubMed ID: 38818652 [TBL] [Abstract][Full Text] [Related]
11. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D Cells; 2024 Mar; 13(6):. PubMed ID: 38534371 [TBL] [Abstract][Full Text] [Related]
13. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders. Diehl CJ; Ciulli A Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982 [TBL] [Abstract][Full Text] [Related]
14. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x Negi A; Voisin-Chiret AS Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486 [TBL] [Abstract][Full Text] [Related]
15. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs. Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445 [TBL] [Abstract][Full Text] [Related]
16. Structural basis of PROTAC cooperative recognition for selective protein degradation. Gadd MS; Testa A; Lucas X; Chan KH; Chen W; Lamont DJ; Zengerle M; Ciulli A Nat Chem Biol; 2017 May; 13(5):514-521. PubMed ID: 28288108 [TBL] [Abstract][Full Text] [Related]
17. Mechanism of degrader-targeted protein ubiquitinability. Crowe C; Nakasone MA; Chandler S; Craigon C; Sathe G; Tatham MH; Makukhin N; Hay RT; Ciulli A Sci Adv; 2024 Oct; 10(41):eado6492. PubMed ID: 39392888 [TBL] [Abstract][Full Text] [Related]
18. Discovery of PROTAC BCL-X Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645 [TBL] [Abstract][Full Text] [Related]
19. The PROTAC selectively degrading Bcl-x Zhang S; Chen Y; Xu Z; Yang J; Sun R; Wang J; Sun Y; Jiang B; Yang X; Tan W Theranostics; 2022; 12(17):7476-7490. PubMed ID: 36438482 [No Abstract] [Full Text] [Related]
20. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Jia Y; Han L; Ramage CL; Wang Z; Weng CC; Yang L; Colla S; Ma H; Zhang W; Andreeff M; Daver N; Jain N; Pemmaraju N; Bhalla K; Mustjoki S; Zhang P; Zheng G; Zhou D; Zhang Q; Konopleva M Haematologica; 2023 Oct; 108(10):2626-2638. PubMed ID: 37078252 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]